News

If you would like to receive future press releases please subscribe here >>

2015

  • 2015-08-20   Axelar and Cadila Pharmaceuticals announce co-development agreement for Non-Small Cell Lung Cancer Treatment. Read more >>
  • 2015-04-08   The Foundation for Baltic and East European Studies (Östersjöstiftelsen) has purchased all KDev Investments AB shares in Axelar AB for an undisclosed up-front payment and earn-out payments. This deal was made as KDev Investments wanted to divest its entire holding to one party. Östersjöstiftelsen will offer the other shareholders in Axelar AB the opportunity to purchase shares pro-rata, as Östersjöstiftelsen, according to their statutes, shall not be a majority owner.

2014

  • 2014-06-02   Axelar presented clinical data on AXL1717 at the American Society of Clinical Oncology annual meeting in Chicago. Download Poster >>

2013

  • 2013-12-27   Axelar announces final data from Phase II study with AXL1717 in lung cancer. Read more >>
  • 2013-04-02   Preliminary results of a Phase II study indicate that Axelar’s AXL1717 is efficacious in 2nd line treatment of patients with lung cancer. Read more >>
  • 2013-01-21   Investigator sponsored Phase I/II study of AXL1717 in patients with brain tumors started in the US. Read more >>

2012

  • 2012-10-01   Axelar AB appoints Carl Harald Janson as CEO. Read more >>
  • 2012-06-02   Axelar AB has presented Phase I/II data of AXL1717 at the American Society of Clinical Oncology (ASCO) Annual Meeting. Read more >>
  • 2012-05-15   Axelar to present at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June 2012. Read more >>

2011

  • 2011-12-28   Axelar initiates a Phase II clinical study with AXL1717 for the treatment of non-small cell lung cancer. Read more >>
  • 2011-09-26   Axelar reports good safety profile of AXL1717 in Phase I/II in cancer patients. Read more >>
  • 2011-07-07   Axelar reports completion of the Phase I/II safety study with AXL1717 in cancer patients. Read more >>
  • 2011-05-11   Axelar secures funding for the coming Phase II program in lung cancer. Read more >>
  • 2011-04-06   Axelar announces positive interim results in Phase I/II study. Read more >>
  • 2011-03-29   Axelar’s AXL1717 to be presented at the American Association of Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida. Read more >>

2010

  • 2010-09-07   First AXL1717 clinical data from ongoing phase I/II study in cancer patients has been published. Read more >>
  • 2010-05-17   AXL1717 clinical data from ongoing phase I/II study in cancer patients will be released in connection with the ASCO meeting in Chicago, June 2010. Read more >>
  • 2010-04-27   Axelar’s board strengthened. Read more >>

2009

  • 2009-11-13   Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA. Read more >>
  • 2009-05-06   Successful Phase I/II Clinical Trial Results from Cancer Patients Treated with Anticancer Drug from Axelar AB. Read more >>

2008

  • 2008-06-17   Axelar initiates phase I/II clinical trial on cancer patients with the new anti-cancer drug AXL1717. Read more >>
  • 2008-06-12   Axelar receives financing for a phase I/II clinical trial on cancer patients with the new anti-cancer drug AXL1717. Read more >>